PharmaNutra SpA (IT:PHN)
:PHN
Want to see IT:PHN full AI Analyst Report?
Top Page
PharmaNutra SpA
(PHN)
Select Model
Select Model
Rating:68Neutral
Price Target:
€98.00
▲(19.95% Upside)
Action:Downgraded
Date:05/17/26
The score is driven primarily by solid balance sheet strength and cash generation, tempered by the major red flag of TTM operating-profit deterioration. Technicals are supportive with a strong uptrend but look overbought, and valuation appears only moderately attractive with a modest dividend yield.
Positive Factors
Strong cash generation
Consistent operating cash flow (~€19–21M) and positive free cash flow (~€16M) provide durable internal funding for capex, R&D, dividends or acquisitions. This cash generation underpins financial flexibility and reduces reliance on external financing over the medium term.
Negative Factors
Sharp operating-profit deterioration
A recent swing to negative operating profit and EBITDA margin materially weakens core earnings quality. If persistent, this undermines operating leverage, erodes the ability to fund growth from operations, and risks reversing prior strong returns on equity and cash-generation metrics.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong cash generation
Consistent operating cash flow (~€19–21M) and positive free cash flow (~€16M) provide durable internal funding for capex, R&D, dividends or acquisitions. This cash generation underpins financial flexibility and reduces reliance on external financing over the medium term.
Read all positive factors
PharmaNutra SpA (PHN) vs. iShares MSCI Italy ETF (EWI)
Market Cap
€896.46M
Dividend Yield1.86%
Average Volume (3M)25.97K
Price to Earnings (P/E)42.2
Beta (1Y)0.41
Revenue Growth16.81%
EPS Growth28.37%
CountryIT
Employees118
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)2.22
Shares Outstanding9,680,977
10 Day Avg. Volume12,507
30 Day Avg. Volume25,966
Financial Highlights & Ratios
PEG Ratio1.25
Price to Book (P/B)7.28
Price to Sales (P/S)3.95
P/FCF Ratio31.63
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€95.50Price Target Upside16.89% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)2.54
Revenue Forecast (FY)€151.87M
PharmaNutra SpA Business Overview & Revenue Model
Company Description
Pharmanutra S.p.A. functions as a pharmaceutical and nutraceutical enterprise, focusing on the research, development, design, and marketing of nutritional supplements and medical devices. Its market reach extends across Italy, other parts of Europ...
How the Company Makes Money
PharmaNutra makes money primarily by selling nutraceutical and medical nutrition products through a combination of (i) direct sales of its own branded portfolio and (ii) business-to-business supply/contract activities. A key revenue stream is the ...
PharmaNutra SpA Financial Statement Overview
Summary
Income Statement
56
Neutral
Balance Sheet
78
Positive
Cash Flow
72
Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 138.65M | 131.69M | 116.15M | 101.03M | 83.39M | 68.14M |
| Gross Profit | 40.77M | 29.71M | 82.79M | 48.95M | 30.17M | 32.15M |
| EBITDA | -4.60M | 34.21M | 32.01M | 26.53M | 24.61M | 19.84M |
| Net Income | 21.02M | 20.00M | 16.61M | 12.83M | 15.05M | 13.77M |
Balance Sheet | ||||||
| Total Assets | 128.13M | 125.23M | 117.47M | 112.44M | 100.16M | 71.36M |
| Cash, Cash Equivalents and Short-Term Investments | 29.00M | 30.61M | 29.10M | 25.12M | 26.86M | 33.94M |
| Total Debt | 19.10M | 20.51M | 24.27M | 28.02M | 17.73M | 6.35M |
| Total Liabilities | 53.65M | 53.99M | 55.27M | 58.04M | 49.21M | 26.27M |
| Stockholders Equity | 74.60M | 71.35M | 62.16M | 54.41M | 50.95M | 45.08M |
Cash Flow | ||||||
| Free Cash Flow | 16.03M | 16.43M | 16.25M | -1.16M | -8.69M | 15.43M |
| Operating Cash Flow | 19.45M | 19.56M | 20.50M | 12.09M | 14.47M | 20.41M |
| Investing Cash Flow | -5.27M | -3.36M | -2.21M | -14.70M | -23.71M | -5.54M |
| Financing Cash Flow | -16.84M | -13.12M | -21.59M | -516.00K | 1.89M | -1.92M |
PharmaNutra SpA Technical Analysis
Positive
81.70
Price Trends
83.24
Positive
74.60
Positive
61.76
Positive
Market Momentum
2.78
Negative
64.15
Neutral
71.78
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IT:PHN, the sentiment is Positive. The current price of 81.7 is below the 20-day moving average (MA) of 89.08, below the 50-day MA of 83.24, and above the 200-day MA of 61.76, indicating a bullish trend. The MACD of 2.78 indicates Negative momentum. The RSI at 64.15 is Neutral, neither overbought nor oversold. The STOCH value of 71.78 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IT:PHN.
PharmaNutra SpA Peers Comparison
UnderperformOutperform
Sector (51)
IT:PHN
PharmaNutra SpA
92.60
43.95
90.35%
IT:GHC
Garofalo Health Care S.P.A.
5.34
0.28
5.55%
IT:ARBS
Arterra Bioscience SpA
2.83
0.64
29.40%
IT:EUK
Eukedos S.p.A.
0.66
-0.15
-18.13%
IT:COSMO
Farmacosmo S.P.A.
0.39
-0.18
-32.06%
IT:SVS
Svas Biosana S.p.A.
9.74
2.02
26.08%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.